Navigation Links
Mylan Reports Q1 2012 Adjusted Diluted EPS of $0.52, an 18% Increase Over Prior Year Quarter
Date:4/26/2012

w product launched in the first quarter was Escitalopram Tablets USP, 5 mg, 10 mg and 20 mg, the first equivalent product to Forest Laboratories' Lexapro®, which is used for acute and maintenance treatment of major depressive disorder and acute treatment of generalized anxiety disorder. The increase in sales from new products was partially offset by lower sales of existing products, principally as a result of lower volumes. The effect of foreign currency translation was insignificant within North America.

Third party net revenues from EMEA were $335.6 million for the quarter ended March 31, 2012, compared to $389.1 million for the comparable prior year period, a decrease of $53.5 million, or 13.7%. Translating current quarter third party net revenues from EMEA at prior year comparative period exchange rates would have resulted in a decline in third party net revenues, excluding the effect of foreign currency, of approximately $39 million, or 10%. This decrease was mainly the result of competitive markets conditions which resulted in unfavorable pricing and volume in many of the European markets in which Mylan operates, partially offset by new product launches throughout the region and increased volume in Italy.

Third party net revenues in Asia Pacific were $298.7 million for the quarter ended March 31, 2012, compared to $276.1 million for the comparable prior year period, an increase of $22.6 million, or 8.2%. Foreign currency translation had a negative impact on sales for the current quarter. Excluding the effect of foreign currency, calculated as described above, the increase was approximately $32 million, or 12%. This increase is primarily driven by higher third party sales from at Mylan Laboratories Limited (formerly Matrix Laboratories Limited), Mylan's subsidiary in India, as a result of an increase in sales of anti-retroviral finished dosage form generic products, which are used in the treatment of HIV/AIDS, as well as higher third-party s
'/>"/>

SOURCE Mylan Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13

Related medicine technology :

1. Mylan and Pfizer Announce Epinephrine Auto-injector Settlement Agreement with Teva
2. Mylan Launches Generic Version of Zyprexa® Tablets
3. Mylan Launches First Generic Version of Lescol® Capsules
4. Mylan Schedules First Quarter 2012 Financial Results Conference Call and Live Webcast
5. Mylan One of First to Launch Generic Version of Boniva®
6. Mylan Canada Receives Health Canada Approval for Generic Version of Crestor®
7. Mylan Continues to Pursue Damages and Injunction Against Sunovions Brovana® in Ongoing Litigation
8. Mylan Pharmaceuticals President Tony Mauro Elected Chairman of GPhA
9. Mylan Secures an Additional $300 Million of Committed Financing
10. Mylan Reports Adjusted Diluted EPS of $0.53 for the Quarter, an 18% Increase Over Prior Year Quarter; and $2.04 for the Year, a 27% Increase Over Prior Year
11. Mylan and Pfizer Announce Epinephrine Auto-injector Settlement Agreement
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2015)... , Aug. 27, 2015  The Academy ... Food and Drug Administration,s (FDA,s) draft guidance and ... products and biosimilars, to bear a nonproprietary name ... has been seeking a decision from the FDA ... diverse health care stakeholders urging the agency to ...
(Date:8/27/2015)... , Aug. 27, 2015 ieCrowd™ ... in the commercial development of the company,s supplemental ... Smart Oxygen device, being developed by ieCrowd,s subsidiary ... a patient,s changing demand for oxygen based on ... 510 (k) submission for the Smart Oxygen device ...
(Date:8/27/2015)... N.J. , Aug. 27, 2015   Women Grow , ... cannabis industry, is partnering with the Cannabis World Congress ... to produce 15 business-focused educational sessions. CWCBExpo in ... Los Angeles Convention Center in ... event on the West Coast for the marijuana industry. ...
Breaking Medicine Technology:AMCP Is Disappointed in FDA's Draft Guidance and Proposed Rule Calling for Suffix on Nonproprietary Names of Biological Products 2Smart Oxygen Solutions' Supplemental Oxygen Delivery Device Achieves FDA Regulatory Pathway Milestone 2Smart Oxygen Solutions' Supplemental Oxygen Delivery Device Achieves FDA Regulatory Pathway Milestone 3Smart Oxygen Solutions' Supplemental Oxygen Delivery Device Achieves FDA Regulatory Pathway Milestone 4Cannabis World Congress in Los Angeles Boasts Women Grow Sponsored Education 2Cannabis World Congress in Los Angeles Boasts Women Grow Sponsored Education 3Cannabis World Congress in Los Angeles Boasts Women Grow Sponsored Education 4
... subsequently,respond, have substantially more treatment costs, and ... COLORADO SPRINGS, Colo., April 03, 2007 /PRNewswire-FirstCall/,-- ... Congress on,Schizophrenia Research (ICOSR) suggest that antipsychotic ... thought, and,challenge the current schizophrenia treatment paradigm ...
... Amyloid Plaque Formation, ANNAPOLIS, Md., April 03, ... company specializing in the development,and commercialization of ... today that new data from its,recombinant butyrylcholinesterase ... 8th International Conference on,Alzheimer's and Parkinson's Diseases ...
Cached Medicine Technology:New Data Show Early Non-Response to Antipsychotic Treatment May Be,Strong Predictor of Subsequent Non-Response for People with,Schizophrenia 2New Data Show Early Non-Response to Antipsychotic Treatment May Be,Strong Predictor of Subsequent Non-Response for People with,Schizophrenia 3New Data Show Early Non-Response to Antipsychotic Treatment May Be,Strong Predictor of Subsequent Non-Response for People with,Schizophrenia 4New Data Show Early Non-Response to Antipsychotic Treatment May Be,Strong Predictor of Subsequent Non-Response for People with,Schizophrenia 5New Data Show Early Non-Response to Antipsychotic Treatment May Be,Strong Predictor of Subsequent Non-Response for People with,Schizophrenia 6PharmAthene's Recombinant Butyrylcholinesterase (rBChE) Program the,Subject of Promising New Alzheimer's Research 2PharmAthene's Recombinant Butyrylcholinesterase (rBChE) Program the,Subject of Promising New Alzheimer's Research 3PharmAthene's Recombinant Butyrylcholinesterase (rBChE) Program the,Subject of Promising New Alzheimer's Research 4PharmAthene's Recombinant Butyrylcholinesterase (rBChE) Program the,Subject of Promising New Alzheimer's Research 5PharmAthene's Recombinant Butyrylcholinesterase (rBChE) Program the,Subject of Promising New Alzheimer's Research 6
(Date:8/29/2015)... , ... August 29, 2015 , ... ... include treating the localized area with stretching, soft tissue manipulation. Platelet rich plasma ... position have shown through research to improve treatment outcomes. This localized treatment ...
(Date:8/28/2015)... ... August 28, 2015 , ... ... management, Decatur County Memorial Hospital recently transitioned management companies to partner with Wound ... Management for their outpatient wound center. , Transitioning wound care management providers ...
(Date:8/28/2015)... , ... August 28, 2015 , ... An article ... local pizza maker Paul LaRocco has gone through to open a pizzeria in Westchester. ... permitting process tends to take several months, but the current process, having already gone ...
(Date:8/28/2015)... ... 28, 2015 , ... As reported by Medical Daily on August 22 ... results that last for two years, the longest of any cellulite reduction system currently ... for a long-lasting, effective solution for their cellulite, according to Dr. Robert Weiss, director ...
(Date:8/28/2015)... ... 28, 2015 , ... Saint Petersburg, FL —Pocket Protein™, a ... carbs, sugar, gluten, lactose or caffeine in a convenient 2 oz. pouch that ... Editor’s Choice Awards. , Five consumer packaged goods (CPG) products were selected by ...
Breaking Medicine News(10 mins):Health News:NEW APPROACH for Treatment of Recurrent Hamstring Strains and Hamstring Tendinosis is Available for the First Time in NYC 2Health News:NEW APPROACH for Treatment of Recurrent Hamstring Strains and Hamstring Tendinosis is Available for the First Time in NYC 3Health News:Decatur County Memorial Hospital Transitions Wound Center Management To Wound Care Advantage and the Luvo Operating System 2Health News:Decatur County Memorial Hospital Transitions Wound Center Management To Wound Care Advantage and the Luvo Operating System 3Health News:Decatur County Memorial Hospital Transitions Wound Center Management To Wound Care Advantage and the Luvo Operating System 4Health News:Article on Building Approval Process for LA Business Highlights the Need for a Bridge Between Businesses and City Officials, says Fire Protection Group Inc. 2Health News:Maryland Dermatologists Discuss Non-Invasive Cellulite Reduction System Cellfina Receiving 2-Year FDA Clearance 2Health News:Maryland Dermatologists Discuss Non-Invasive Cellulite Reduction System Cellfina Receiving 2-Year FDA Clearance 3Health News:Pocket Protein™ Named 2015 CPG Editor’s Choice Award Finalist by Informa’s SupplySide 2Health News:Pocket Protein™ Named 2015 CPG Editor’s Choice Award Finalist by Informa’s SupplySide 3
... Digirad Corporation,(Nasdaq: DRAD ), a leading provider ... offices, hospitals and imaging centers, today,announced that it ... Program,for San Diego. The prestigious honor recognizes the ... in the,San Diego area based on percentage revenue ...
... NEW YORK, Oct. 15 Highlands Acquisition Corp.,(Amex: ... for,the Company,s initial public offering have exercised in ... public offering. As,a result, the Company sold an ... share of common stock and one warrant to ...
... SEOUL, South Korea, Oct. 15 Dong-A PharmTech Co. ... contract with,Otechestvennye Lekarstva OJSC, to market in Russia Dong-A,s ... the brand name of,Zydena. Under the terms of ... pharmaceutical firms, will pay both upfront fees and,running royalty ...
... Ended 2007, BANGOR, Maine, Oct. 15 Nyer Medical ... results for its,fiscal year ended June 30, 2007. Revenues increased ... compared to $63,596,975 as reported for,the same period ended June ... $.02 basic net earnings per common share for the year ...
... Findings could bring new treatment options for patients, ... -- Surgery patients may one day find nicotine ... prescription pad, researchers say. , Nicotine patches and ... following surgery, according to two studies presented at ...
... FORT WORTH, Texas, Oct. 15 DSS Research asked ... around PFFS sales,practices in their June Senior Trax(TM) survey. ... Medicare eligibles. Overall, 13.3% said they,had heard or read ... past two months. This figure ranged from a high ...
Cached Medicine News:Health News:Digirad Corporation Named to Deloitte Technology Fast 50 2Health News:Digirad Corporation Named to Deloitte Technology Fast 50 3Health News:Highlands Acquisition Corp. Announces Exercise of Over-Allotment Option 2Health News:Dong-A PharmTech Signs Licensing Deal With Otechestvennye to Market Zydena in Russia 2Health News:Nyer Medical Group, Inc. Reports EPS of $.02 on Record Revenues of $69.9 Million for Fiscal Year Ended 2007 2Health News:Nyer Medical Group, Inc. Reports EPS of $.02 on Record Revenues of $69.9 Million for Fiscal Year Ended 2007 3Health News:Nyer Medical Group, Inc. Reports EPS of $.02 on Record Revenues of $69.9 Million for Fiscal Year Ended 2007 4Health News:Nicotine, Chili Peppers Offer Post-Surgery Pain Relief 2Health News:Nicotine, Chili Peppers Offer Post-Surgery Pain Relief 3
Clinical micro clamps by Acland. Matte finish. It provides impressive security in use, both against slippage and against leakage due to controlled closing force and working grip surface....
Clinical micro clamps by Acland. Matte finish. It provides impressive security in use, both against slippage and against leakage due to controlled closing force and working grip surface....
Extremely fine straight....
Curved delicate 5 mm blades....
Medicine Products: